创新药继续活跃，港股医药ETF(159718.SZ)现涨超2%，刷年内新高

Group 1 - The innovation drug sector is experiencing a strong positive sentiment, with the Hong Kong pharmaceutical ETF (159718.SZ) rising by 2.01%, marking a six-day consecutive increase and an annual gain of nearly 84%, reaching a new net value high [1] - Key stocks in the sector, such as MicroPort Medical (00853), Innovent Biologics (01801), and WuXi AppTec (02359), have shown significant price increases, indicating robust market performance [1] - The overall crowding level in the pharmaceutical sector is at a historical average, with innovation drugs being relatively crowded, while the CXO sector shows lower crowding; the CXO sector is expected to recover strongly due to favorable conditions such as potential interest rate cuts by the Federal Reserve and improved investment environment in pharmaceuticals [1] Group 2 - The Hong Kong pharmaceutical ETF focuses on 18A biotech companies, including key players like BeiGene, WuXi Biologics, and CSPC Pharmaceutical, benefiting from global innovation drug development [2] - The combination of policy benefits, international expansion, and profit realization is driving the revaluation of Hong Kong pharmaceutical stocks, suggesting a positive outlook for the Hong Kong pharmaceutical ETF (159718.SZ) and its associated funds [2]